Open Access

A decade of innovation, guidelines and paradigm shifts in LDL-C management (10th annual symposium)

Event: ESC Congress 2022
Topic: Lipid-Lowering Agents
Session type: Satellite Symposium
Organised by PACE-CME - Supported by an unrestricted educational grant from Novartis, Sanofi, Daïchi Sankyo, New Amsterdam & other sponsors
Date: 26 August 2022
Time: 12:45 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

Introduction: changing paradigms in LDL-c reduction.

Speaker: Professor K. Ray (London, GB)
Thumbnail

LDC-c: new insights into its role as causal risk factor and target for therapy

Speaker: Professor B. Ference (Cambridge, GB)
Thumbnail

Targeting the PCSK9 pathway: where do novel therapies fit in?

Speaker: Associate Professor A. Navar (Dallas, US)
Thumbnail

Addressing the unmet needs in LDL-c lowering: what can we expect?

Speaker: Professor J. Kastelein (Amsterdam, NL)
Thumbnail

Discussion.

Speaker: Professor K. Ray (London, GB)
Thumbnail

5 speakers from this session

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
3 followers

Professor Brian A Ference

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)
27 presentations
3 followers

Associate Professor Ann Marie Navar

University of Texas Southwestern Medical Center, Dallas (United States of America)
1 presentation
1 follower

Professor John Kastelein

Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))
21 presentations
1 follower

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
3 followers

This platform is supported by

logo Novo Nordisk